Sponsor Overview
Explore verified public information about UNION therapeutics's expanded access programs, compassionate use policies, and patient eligibility pathways. This report aggregates official statements, independent research, and regulatory data to help patients, providers, and sponsors collaborate efficiently.
Unique references curated across 2 content categories.
ClinicalTrials.gov data sources power this status.
Dataset refreshed continuously through Right2Hope ETL pipelines.
Expanded Access Intelligence
Official Statements
Score contribution: 100 — 1 supporting sources.
“As part of UNION’s market access and affordability strategy, the company is committed to: - Exploring opportunities by initiating expanded access programs in which UNION could provide patients with access to UNION’s investigational products through long-term clinical trials.”
Reagan-Udall Foundation Insights
Single-Patient EA Policies/Criteria At this point of clinical development, UNION has not established an Expanded Access Program that allows patients access to orismilast outside of clinical trials. Participation in clinical trials will ensure dedicated monitoring of the efficacy and safety of the drug, which is currently the most appropriate and responsible setting of patient treatment. Disease/Category-Specific EA Policies/Criteria https://uniontherapeutics.com/wp-content/uploads/2023/01/UNION-therapeutics_Expanded-Access_final.pdf
Partner with Right2Hope
Right2Hope helps sponsors translate regulatory programs into actionable patient access pathways. Connect with our team to publish new programs, streamline intake workflows, or align with providers seeking compassionate use options.